DEP® irinotecan
DEP® irinotecan is a novel, patented nanoparticle formulation of SN-38, the active metabolite of irinotecan, delivered using Starpharma’s proprietary DEP® technology. DEP® irinotecan has shown a number of benefits compared to the original form of irinotecan, including significant improvements in anti-cancer efficacy and improved survival in multiple human cancer models. DEP® irinotecan is the third DEP® product to enter the clinic from Starpharma’s internal portfolio.
Product families
Applications
- Other Medical Applications
Product Families
- Active Pharmaceutical Ingredients (APIs)
Other characteristics
- Brand
- DEP
- Markets
- Healthcare & Pharma
- Features
DEP® irinotecan is a novel, patented nanoparticle formulation of SN-38, the active metabolite of irinotecan, delivered using Starpharma's proprietary DEP® technology.; Irinotecan (Camptosar®) is a major cancer drug used to treat colorectal cancer with peak global sales of >US$1.1 billion despite having multiple US FDA "Black Box" warnings. Irinotecan is a pro-drug that requires conversion to its active metabolite, SN38. The need for this conversion may lead to variable clinical effect/efficacy and toxicity among patients.; DEP® solubilises SN38 and allows direct dosing, avoiding the need for liver conversion. DEP® irinotecan has been shown to demonstrate improved efficacy in multiple animal models and has patent filings to 2039 (plus up to an additional ~5 years).
- Technology
- Pharmaceuticals & Nutraceuticals
